Otava, a chemical and drug-discovery company, is offering more than 200 new focused compound libraries for screening.
These target-specific compound libraries include P38 kinase inhibitors, cathepsin B inhibitors and HCV serine protease inhibitors, as well as compounds with other pharmacological activities, such as antiallergic, antiviral and analgesic.
These focused libraries were specially designed for the research and development of lead compounds.
The libraries were prepared by virtual screening using a ligand-based approach.
The prediction of a specific biological activity is based on the analysis of quantitative structure-activity relationships (QSARs) of a training set that includes more than 40,000 known biologically active substances.
Each library contains only drug-like compounds.
All compounds from the libraries are in stock and they are available on a cherry-pick basis in vials and/or microplates according to specifications.
Customers can also order an entire library.
